{"id":"W3116484428","doi":"10.1177/1756287220980192","title":"Enfortumab Vedotin in urothelial cancer","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Oncology; Internal medicine; Clinical trial; Durvalumab; Cancer; Urothelial cancer; Rash; Population; Bladder cancer; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000123114,0.0005745245,0.002590435,0.0003230218,0.00002522197,0.000007170744,0.0002833967,0.0004314937,0.0005916303],"category_scores_gemma":[0.00002494527,0.0004511568,0.0002956681,0.0005551475,0.0001690045,0.00008718099,0.00006584852,0.0009566106,0.0001323949],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003989652,"about_ca_system_score_gemma":0.001058091,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001079959,"about_ca_topic_score_gemma":0.0003064465,"domain_scores_codex":[0.9974456,0.0002389576,0.0008051656,0.0007100352,0.0002116082,0.0005886423],"domain_scores_gemma":[0.999038,0.0001902652,0.0002398635,0.0003871286,0.00002142992,0.0001233008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000350737,0.000140384,0.0003207351,0.002461165,0.000151202,0.0003484273,0.0001445978,0.000007038734,4.311531e-7,0.0002582523,0.000009284248,0.9958078],"study_design_scores_gemma":[0.002199419,0.0005713514,0.00005547929,0.001514391,0.0007654374,0.0001365948,0.00001095315,0.00001516127,0.00000138043,0.0007434495,0.993676,0.0003103575],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000007100833,0.9931781,0.00005068021,0.0003819059,0.0006956205,0.001523705,0.00006139436,0.00005949616,0.004041944],"genre_scores_gemma":[0.0007011511,0.9956614,0.00007062419,0.001826761,0.0004696288,0.0008822269,0.00004418088,0.0001120752,0.0002319634],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9954974,"threshold_uncertainty_score":0.999794,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05086007436376948,"score_gpt":0.4063818328462285,"score_spread":0.355521758482459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}